Cost Avoidance and Noteworthy Medication Adherence in Year-One Outcomes. FlyteHealth's approach was found to have an 86% adherence rate among new GLP-1 users and cost avoidance of up to $1.2 million within the pilot year of the program.
Cost Avoidance and Noteworthy Medication Adherence in Year-One Outcomes. FlyteHealth's approach was found to have an 86% adherence rate among new GLP-1 users and cost avoidance of up to $1.2 million within the pilot year of the program.